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Clinical and experimental data indicate that anti-neu-
trophil cytoplasmic autoantibodies (ANCAs) cause
glomerulonephritis and vasculitis. Here we report the
first evidence that complement is an important medi-
ator of ANCA disease. Transfer of anti-myeloperoxi-
dase (MPO) IgG into wild-type mice or anti-MPO
splenocytes into immune-deficient mice caused cres-
centic glomerulonephritis that could be completely
blocked by complement depletion. The role of spe-
cific complement activation pathways was investi-
gated using mice with knockout of the common path-
way component C5, classic and lectin binding
pathway component C4, and alternative pathway
component factor B. After injection of anti-MPO IgG,
C4/ mice developed disease comparable with wild-
type disease; however, C5/ and factor B/ mice
developed no disease. To substantiate a role for com-
plement in human ANCA disease, IgG was isolated
from patients with myeloperoxidase ANCA (MPO-
ANCA) or proteinase 3 ANCA (PR3-ANCA) and from
controls. Incubation of MPO-ANCA or PR3-ANCA IgG
with human neutrophils caused release of factors that
activated complement. IgG from healthy controls did
not produce this effect. The findings suggest that stim-
ulation of neutrophils by ANCA causes release of fac-
tors that activate complement via the alternative path-
way, thus initiating an inflammatory amplification
loop that mediates the severe necrotizing inflamma-
tion of ANCA disease. (Am J Pathol 2007, 170:52–64; DOI:
10.2353/ajpath.2007.060573)
Anti-neutrophil cytoplasmic autoantibodies (ANCA) are
specific for proteins in the cytoplasm of neutrophils and
monocytes. The major target antigens in patients with
vasculitis and glomerulonephritis are myeloperoxidase
(MPO) and proteinase 3 (PR3). ANCAs occur in greater
than 80% of patients with active untreated Wegener’s
granulomatosis, microscopic polyangiitis, and pauci-im-
mune crescentic glomerulonephritis.1 There is compel-
ling clinical and experimental evidence that ANCA IgG
causes ANCA-associated vasculitis and glomerulone-
phritis. The strongest clinical evidence for causation is
the observation that a newborn child developed glomer-
ulonephritis and pulmonary hemorrhage shortly after de-
livery from a mother with MPO-ANCA-associated micro-
scopic polyangiitis, apparently caused by transplacental
transfer of ANCA IgG.2,3 Two compelling animal models
of ANCA vasculitis and glomerulonephritis have been
described by two different research groups.4,5 Xiao and
colleagues4 induced glomerulonephritis and systemic
vasculitis by intravenous injection of either anti-MPO IgG
or anti-MPO splenocytes derived from MPO knockout
mice immunized with murine MPO. Induction of glomer-
ulonephritis by anti-MPO IgG in this model is enhanced
by cytokines6 and requires neutrophils.7 Little and col-
leagues5 immunized rats with human MPO, resulting in
the production of antibodies that cross reacted with rat
MPO and caused vasculitis and glomerulonephritis. The
pathogenic effects of these anti-MPO antibodies were
augmented by cytokines.
Numerous in vitro studies indicate that ANCA IgG
can activate neutrophils and cause them to release
proinflammatory factors. The expression of ANCA an-
tigens (MPO and PR3) at the surface of neutrophils
where they are accessible to interact with ANCA IgG is
enhanced by proinflammatory cytokines, such as tu-
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mor necrosis factor (TNF)-.8,9 Incubation of TNF--
primed neutrophils with ANCA IgG induces full activa-
tion with release of lytic and toxic granule enzymes and
reactive oxygen species.8,9 Interaction of ANCA IgG
with ANCA antigens in the microenvironment of neutro-
phils causes activation through both Fc receptor en-
gagement and Fab2 binding.10 –13 Activation of neu-
trophil by ANCA IgG in the presence of cultured
endothelial cells results in neutrophil adherence,14
neutrophil transmigration,15 and endothelial cell
death.16,17 Little and colleagues5 have documented
this process in vivo using their rat model to show by
intravital microscopy that leukocytes activated with
MPO-ANCA IgG adhere to and injure the
microvasculature.
Before the observations reported in this article, a role
for complement in the pathogenesis of ANCA-induced
inflammation has not been suspected. This is in part
because there is less complement deposition in vessel
walls in ANCA vasculitis and glomerulonephritis as com-
pared with the substantial complement deposition that is
observed with immune complex disease and anti-glomer-
ular basement membrane disease.18,19 However, an im-
portant mediator of vascular inflammation does not have
to be present in vessel walls at high concentrations. For
example, there is a paucity of IgG in the vascular lesions
of ANCA vasculitis and glomerulonephritis, yet, as re-
viewed earlier, there is compelling evidence that ANCA
IgG is the primary pathogenic factor causing these in-
flammatory lesions. ANCA disease is not associated with
hypocomplementemia; however, this is not a sensitive
indicator of complement involvement because certain
forms of glomerulonephritis and vasculitis that have sub-
stantial vascular deposits of complement do not have
hypocomplementemia, such as Henoch-Schönlein pur-
pura and anti-GBM disease. In addition, complement
activation has been identified as a major mediator of
injury and inflammation in a variety of diseases in which
there is little or no complement localization at the site of
injury, for example, complement activation, probably
through the alternative pathway, is an important mediator
in ischemia reperfusion injury.20 The complement system
can be activated through three different pathways: clas-
sic, lectin, and alternative.21–23 Among the many factors
that can activate complement are mediators released by
activated neutrophils.24–27 Based on the observations
reported herein, we hypothesize that ANCA-induced ac-
tivation of neutrophils results in the release of factors that
activate the alternative complement pathway amplifica-
tion loop, which in turn augments recruitment and activa-
tion of more neutrophils, resulting in the severe necrotiz-
ing leukocytoclastic inflammation that is so characteristic
of acute ANCA disease.
Materials and Methods
Mice
MPO knockout (Mpo/) mice initially generated by Ara-
tani and colleagues28 were maintained by the University
of North Carolina Division of Laboratory Animal Medicine.
Mpo/ mice (8 to 10 weeks old) were used for immuni-
zation and as donors of anti-MPO antibodies and spleno-
cytes. Rag2 mice were purchased from Taconic Farms
(Germantown, NY). Factor B/ mice that were initially
generated by Matsumoto and colleagues29 were kindly
provided by Dr. Zhi Liu, Department of Dermatology,
University of North Carolina, Chapel Hill, NC. Age- and
sex-matched wild-type (WT) B6 controls, C4/ mice,
and C5/ mice were purchased from Jackson Labora-
tory (Bar Harbor, ME). All complement-deficient mice had
a C57BL/6 (B6) background. Rag2/ mice, 10 to 12
weeks old, were used as recipients for adoptive spleno-
cyte transfer experiments. Factor B/, C4/, C5/,
and WT B6 mice, 9 to 10 weeks old, were used for IgG
transfer experiments. All animal experiments were ap-
proved by the Animal Studies Committee of the University
of North Carolina at Chapel Hill, School of Medicine, and
were used in accordance with National Institutes of
Health guidelines.
Kinetics of C3 Depletion by Cobra Venom
Factor (CVF)
To determine the kinetics of C3 depletion by CVF, WT B6
mice (n  6) were injected intraperitoneally with a single
dose of 30 g of CVF (Sigma-Aldrich, St. Louis, MO) in
0.3 ml of phosphate-buffered saline (PBS). Control mice
(n  6) received 0.3 ml of PBS. Serum C3 levels was
measured on days 0, 1, 3, 5, 7, 9, 11, and 13 after
injection of CVF by C3 antibody capture enzyme-linked
immunosorbent assay (ELISA) using F(ab)2 fragments of
goat anti-mouse C3 as capture antibody and peroxidase-
conjugated goat anti-mouse C3 as the second antibody
(Cappel, Organon Teknika Corporate, West Chester, PA),
according to the manufacturer’s protocol. C3 levels mon-
itored by ELISA were markedly reduced with the lowest
level within 24 hours after injection and remained at this
low level for up to 7 days. Thereafter, C3 returned toward
normal and reached the normal level at approximately
day 11. Control mice injected with the same volume of
PBS exhibited normal levels of circulating C3 (Figure 1).
Preparation of Nephritogenic Mouse Anti-
Murine MPO Splenocytes and Antibodies
Purification of mouse MPO and the immunization of
Mpo/ mice were performed as previously described.4
In brief, mouse MPO was purified from WEHI-3 cells by
Dounce homogenization, Concanavalin A affinity chro-
matography, ion exchange, and gel filtration chromatog-
raphy. Mpo/ mice were immunized intraperitoneally
with 10 g of purified murine MPO or bovine serum
albumin in complete Freund’s adjuvant and subsequently
boosted with antigen in incomplete Freund’s adjuvant.
Development of antibodies was monitored by ELISA and
anti-MPO antibody reactivity with neutrophils was con-
firmed by indirect immunofluorescence microscopy on
murine neutrophils. The IgG fraction was isolated from
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serum by 50% ammonium sulfate precipitation and pro-
tein G affinity chromatography. Splenocytes were iso-
lated from immunized and nonimmunized Mpo/ mice
by disrupting the spleens into cold RPMI 1640 medium
and then washing twice with RPMI 1640. Red blood cells
were removed with lysis buffer (Sigma-Aldrich) followed
by washing with RPMI 1640 and final suspension in sterile
PBS.
Induction of Glomerulonephritis with Anti-MPO
IgG and Anti-MPO Splenocytes
Induction of experimental necrotizing and crescentic glo-
merulonephritis (NCGN) with anti-MPO IgG in WT mice or
anti-MPO splenocytes in Rag2/ immune-deficient mice
was performed as previously described.4 Briefly, in anti-
body transfer experiments, mice were injected intrave-
nously with 50 g/g body weight (BW) of anti-MPO or
control IgG in PBS and sacrificed on day 6. In splenocyte
transfer experiments, Rag2/ mice were injected intra-
venously with 5  107 anti-MPO or control splenocytes in
0.5 ml of PBS and sacrificed on day 13. At the point of
sacrifice, serum and urine samples were collected to
evaluate kidney disease, and serum samples also were
collected for serological assays of antibody and comple-
ment activity.
In IgG transfer CVF complement depletion experi-
ments, WT and control mice received intravenously 50
g/g BW of anti-MPO IgG 4 hours after injection of one
dose of CVF or PBS, respectively, and were sacrificed on
day 6. The effect of CVF on circulating complement was
determined by C3 antibody capture ELISA. The urine,
serum, and kidney tissue samples were collected for
further evaluation as below.
In splenocyte transfer CVF complement depletion ex-
periments, Rag2/ mice were injected intraperitoneally
with 30 g of CVF in 0.3 ml of PBS on days 0 and 6, and
control mice received 0.3 ml of PBS on days 0 and 6.
Both experimental and control mice received 5  107
anti-MPO splenocytes by intravenous injection 4 hours
after receiving the first dose of CVF or PBS. The mice
were sacrificed on day 13.
In IgG transfer experiments in complement knockout
mice, C5/, C4/, fB/, or WT mice were injected
intravenously with 50 g/g BW of anti-MPO IgG and
sacrificed on day 6. The urine, serum, and kidney tissues
were collected for evaluation.
Functional Evaluation of Renal Injury
Mice were placed in metabolic cages 1 day before sac-
rifice and urine was collected for 12 hours. Urine was
tested by dipstick (Roche Diagnostics Corp., Indianapo-
lis, IN) for hematuria and leukocyturia. The extent of he-
maturia and leukocyturia was expressed as the mean on
a scale of 0 (none) to 4 (severe). Albuminuria was deter-
mined by a mouse albumin ELISA quantitation kit (Bethyl
Laboratories Inc., Montgomery, TX). Using the mean  2
SDs for the reference range established in 305 healthy B6
mice, abnormal hematuria was set at 0.9 and leukocy-
turia 0.2.7 Serum samples were collected at the time of
sacrifice. Serum creatinine and blood urea nitrogen were
measured using a Johnson & Johnson Ortho-Clinical Di-
agnostics VITROS 250 (Raritan, NJ).
Pathological Evaluation of Renal Injury
Samples of kidney tissue were collected at the time of
sacrifice and fixed in 10% formalin, embedded in paraffin
using routine protocols, sectioned at 4-m, stained with
hematoxylin and eosin and periodic acid Schiff, and eval-
uated by light microscopy. The extent of glomerular cres-
cents and necrosis were expressed as the mean percent-
age of glomeruli with crescents and necrosis in each
animal.
For immunofluorescence microscopy to detect glomer-
ular localization of immune determinants, 4-m frozen
sections were stained with fluorescein isothiocyanate-
conjugated goat anti-mouse IgG (Molecular Probes In-
vitrogen, Carlsbad, CA), IgM, IgA, and MPO (ICN/Cap-
pel, Aurora, OH), respectively. Deposition of complement
C3 was visualized with fluorescein isothiocyanate-conju-
gated goat anti-mouse C3 (ICN/Cappel). Immunofluores-
cence microscopy staining of glomeruli for IgG, IgM, IgA,
C3, and MPO was expressed as the mean intensity of
staining on a scale of 0 (none) to 4 (severe).
For immunohistochemistry to detect renal leukocytes
infiltration, 4-m frozen sections were stained with rat
anti-mouse neutrophil Gr-1 (clone RB6-8C5; BD Pharm-
ingen, Franklin Lakes, NJ) and rat anti-mouse monocytes/
macrophages CD68 antibodies (clone FA11; Serotec,
Raleigh, NC). Rat antibody binding was detected using
peroxidase-conjugated secondary rabbit anti-rat IgG and
tertiary goat anti-rabbit IgG antibodies (DAKO, Carpinte-
ria, CA). Staining was visualized with 3-amino-9-ethylcar-
bazole and hydrogen peroxide. Sections were counter-
stained with hematoxylin. Leukocyte localization was
expressed as the mean number of leukocytes per cross-
Figure 1. Profile of depletion of circulating complements by CVF. WT mice
were given a single intraperitoneal injected dose of CVF (30 mg/0.3 ml PBS)
or PBS (0.3 ml) and the kinetics of complement depletion were monitored by
ELISA analysis of circulating C3 at indicated days after injection. Open
squares represent data from CVF-treated mice (n  6). Filled squares
represent control mice that received PBS (n  6). Bars indicate the SD.
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section of glomeruli based on evaluating an average of
75 glomeruli per specimen (range, 60 to 90 glomeruli).
Measurement of Complement Activation by
Factors Released by ANCA-Stimulated Human
Neutrophils
IgG from healthy controls (n  8), MPO-ANCA patients
(n  6), or PR3-ANCA patients (n  8) was prepared
from plasma by ammonium sulfate precipitation and
protein G affinity column chromatography. IgG prepa-
ration were passed over AffinityPak endotoxin removal
columns (Pierce, Rockford, IL) before use. The plasma
was obtained during plasma exchange on ANCA-pos-
itive patients with active, biopsy-proven necrotizing
and crescentic glomerulonephritis. The patients also
were receiving immunosuppressive treatment. Neutro-
phils were isolated from healthy volunteers using Ficoll
sedimentation. Neutrophils from a single donor were
used for each experimental run that compared the
effect of control IgG to various experimental prepara-
tions. Autologous serum was obtained from the same
donors as the neutrophils. In preparation to determina-
tion of the ability of IgG to stimulate neutrophils to
release complement-activating factors, neutrophils
were primed for 15 minutes at 37°C with 2 ng/ml TNF-.
The primed neutrophils then were incubated with 200
g/ml of either control IgG, MPO-ANCA IgG, or PR3-
ANCA IgG for 15 minutes at 37°C. Additional controls
included reaction mixtures that contained control IgG,
MPO-ANCA IgG, or PR3-ANCA IgG but no neutrophils
(to determine whether the IgG alone could activate
complement) and reaction mixtures that contained
TNF-primed neutrophils but no immunoglobulin (to de-
termine whether primed neutrophils alone could acti-
vate complement). The reaction mixtures were centri-
Figure 2. Mice depleted of complement are resistant to anti-MPO IgG-induced experimental glomerulonephritis. WT mice were pretreated with a single dose of
CVF or PBS (n  7 for each group). Four hours later, the mice received anti-MPO IgG (50 g/g body weight). A and B: Urine analysis showed that untreated
mice and complement-depleted mice that received anti-MPO IgG had no urine abnormalities, whereas noncomplement-depleted mice that received anti-MPO IgG
had albuminuria, hematuria, and leukocyturia. C and D: ELISA analysis demonstrated the same circulating anti-MPO IgG titers in noncomplement-depleted and
complement-depleted mice (C); and low circulating C3 in complement-depleted mice (D). Extent of hematuria and leukocyturia is expressed as the mean on a
scale of 0 (none) to 4 (severe). *P  0.05 and #P  0.001 versus untreated WT. **P  0.004 compared with noncomplement-depleted mice. Bars represent the
mean  SD.
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Figure 3. Renal tissue was examined 6 days after mice received anti-MPO IgG. WT mice that received pathogenic IgG without complement depletion developed
focal glomerular necrosis (long arrow) and crescents (short arrows) (A) and low-level glomerular IgG (B) and C3 (C) deposition. In contrast, the mice depleted
of complement had no glomerular lesions after the same dose of anti-MPO IgG (D) and had no IgG (E) or C3 (F) in glomeruli. A and D are stained with PAS.
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fuged at 300 g for 5 minutes at 4°C. A 100-l aliquot of
supernatant was added to precooled tubes containing
100 l of autologous serum and incubated for 1 hour at
37°C. The reaction was stopped by adding ethyl-
enediaminetetraacetic acid to a final concentration of
10 mmol/L. The supernatants were stored frozen at
70°C until assayed for C3a. C3a, which is a sensitive
marker of complement activation, was assayed in the
supernatant using the Quidel C3a EIA kit (Quidel Corp.,
San Diego, CA) by the manufacturer’s instructions. All
determinations were made in duplicate. Two or more
control IgG samples were included with each assay,
and results for individual control and experimental
samples were expressed as a percentage of the result
of the control IgG mean.
Results
Complement Is Required for Induction of
Glomerulonephritis by Anti-MPO IgG
Pauci-immune NCGN that closely mimics human ANCA
glomerulonephritis is induced in mice by a single injec-
tion of anti-MPO IgG derived from Mpo/ mice that have
been immunized with mouse MPO.4,6,7 By day 6, all mice
that receive anti-MPO IgG develop segmental fibrinoid
necrosis and crescents in 5 to 15% of glomeruli. Immu-
nohistology demonstrates only mild staining for immuno-
globulins and complement. The effect of complement
depletion on the induction of NCGN in this model was
evaluated. WT B6 mice were pretreated with (n  7) or
without (n  7) a single intraperitoneal injection of CVF 4
hours before injection of anti-MPO IgG. Six days after
injecting anti-MPO IgG, all mice that did not have com-
plement depletion developed albuminuria, leukocyturia,
and hematuria whereas the mice that received CVF
stayed within the reference range (Figure 2, A and B). At
the time of sacrifice, mice that received CVF had the
same level of circulating anti-MPO IgG (Figure 2C) as the
mice that did not receive CVF; however, as expected,
they had decreased serum C3 levels (Figure 2D). All of
the mice that received anti-MPO IgG without CVF devel-
oped NCGN with neutrophil and macrophage infiltration
and low-level glomerular IgG and C3 deposition (Figure
3, A–C; and Tables 1 and 2). In contrast, none of the
complement-depleted mice injected with the same dose
of anti-MPO IgG developed glomerular necrosis or cres-
cents (Figure 3, D–F; and Tables 1 and 2). The mice that
did not receive CVF had a paucity of staining for C3
(0.5	) and mice that received CVF had no staining for C3
(Table 2).
Complement Is Required for Induction of NCGN
by Anti-MPO Splenocytes
Intravenous administration of anti-MPO splenocytes
causes more severe disease than injection of anti-MPO
IgG, although it is complicated by a background of im-
mune complex disease.4 In our previously reported ex-
periments,4 all mice that received 1  108 or 5  107
anti-MPO splenocytes developed NCGN with crescents
in 80% of glomeruli. None of the mice that received 1 
107 anti-MPO splenocytes developed NCGN. Immuno-
histology demonstrates a moderate accumulation of im-
munoglobulins and complement in glomeruli of mice that
receive either anti-MPO splenocytes or control spleno-
cytes. The effect of complement depletion with CVF was
evaluated in this more aggressive form of NCGN induced
by anti-MPO splenocytes. Rag2/ mice were treated
intraperitoneally with two doses of 30 g of CVF in 0.3 ml
of PBS (n  8) or PBS alone (n  8) at day 0 and day 6.
Four hours after injection of the first dose of either CVF
(n  8) or PBS (n  8), mice received an intravenous
injection of 5  107 splenocytes from Mpo/ mice that
had been immunized with mouse MPO. Control Rag2/
mice received no CVF and no splenocytes. On day 13, all
mice injected with anti-MPO splenocytes without comple-
ment depletion developed albuminuria, hematuria, leuko-
cyturia, elevated serum creatinine, and elevated blood
urea nitrogen (Figure 4, A–D). In contrast, mice with
complement depletion injected with anti-MPO spleno-
cytes had unremarkable urine findings, creatinine, and








Anti-MPO IgG WT 100 11.3  1.2 5.3  1.2 0.48  0.17 0.82  0.21
Anti-MPO IgG 	 CVF WT 0 0.0  0.0 0.0  0.0 0.07  0.03 0.10  0.04
Anti-MPO splenocytes Rag2/ 100 36.5  21.5 35.8  15.4 2.39  0.47 1.76  0.19
Anti-MPO splenocytes
	 CVF
Rag2/ 0 0.0  0.0 0.0  0.0 0.21  0.07 0.11  0.06
Table 2. Immunofluorescence Microscopy Observations in ANCA Mouse Models with and without CVF Complement Depletion
Group IgG (0 to 4	) IgM (0 to 4	) IgA (0 to 4	) C3 (0 to 4	) MPO (0 to 4	)
Anti-MPO IgG 0.5  0.0 0.4  0.3 0.5  0.0 0.5  0.0 0.0  0.0
Anti-MPO IgG 	 CVF 0.5  0.0 0.3  0.3 0.7  0.3 0.0  0.0 0.0  0.0
Anti-MPO splenocytes 3.0  0.0 1.0  0.0 2.0  0.0 2.5  0.6 0.4  0.3
Anti-MPO splenocyte 	 CVF 0.8  0.3 0.3  0.3 0.8  0.3 0.2  0.3 0.0  0.0
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Figure 4. Complement depletion by CVF abolishes the development of urine abnormalities, and elevation of serum blood urea nitrogen and creatinine in Rag2/
mice 13 days after they received 5  107 anti-MPO splenocytes (A–D). Bars represent the SD. *P  0.05, **P  0.01, #P  0.001 compared with untreated Rag2/
mice (ie, with no anti-MPO splenocytes and no CVF).
Figure 5. Complement depletion prevents anti-MPO splenocyte-induced glomerular necrosis and crescents. Rag2/ mice were treated with CVF or PBS (n 
8 per group), and then, 4 hours later, were injected with 5  107 anti-MPO splenocytes. Pathological examinations were performed at day 13 of receiving anti-MPO
splenocytes. In noncomplement-depleted Rag2/ mice, transfer of anti-MPO splenocytes induced glomerular necrosis (long arrow) and crescent formation
(short arrow) (A) (H&E), moderate glomerular IgG deposition (B) (fluorescein isothiocyanate anti-IgG), and neutrophil and macrophage infiltration (C, D).
Complement-depleted Rag2/ mice that received anti-MPO splenocytes had no lesions by light microscopy (E) (H&E), low-level IgG deposition (F), and no
significant increase in glomerular neutrophils or macrophages (G, H).
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blood urea nitrogen that did not differ significantly from-
mice that received neither CVF nor anti-MPO splenocytes
(Figure 4, A–D). Pathological evaluation of kidneys re-
vealed that all noncomplement-depleted mice that re-
ceived anti-MPO splenocytes developed severe NCGN
with glomerular neutrophil and macrophage infiltration
(Figure 5, A–D; and Table 1). In contrast, none of the
complement-depleted mice that received anti-MPO
splenocytes developed glomerular necrosis or crescents
or increased infiltration of inflammatory cells (Figure 5,
F–H; and Table 1). There was a marked decrease in
circulating C3 in mice given CVF that occurred within 2
days and persisted throughout the experiment (Figure
6A). There was no significant decrease in C3 levels in the
mice that received splenocytes but no CVF. Both non-
complement-depleted and complement-depleted mice
developed circulating anti-MPO antibodies within 2 days,
and the titers steadily increased at similar levels until
sacrifice at 13 days after receiving anti-MPO splenocytes
(Figure 6B). Previous experiments have demonstrated
that immune-deficient Rag2/ mice that receive spleno-
cytes from immune-competent mice develop an immune
complex mediated mesangioproliferative glomerulone-
phritis without crescents.4 Severe crescent formation is
induced only when the splenocytes are derived from
Mpo/ mice that have been immunized with MPO.4
Thus, the anti-MPO immune response and not the im-
mune complex glomerulonephritis is the cause for the
NCGN in this model. In the current experiments, the
interpretation of the blockade of NCGN by CVF after
anti-MPO splenocyte transfer is complicated by the
marked reduction of immune complexes and comple-
ment deposition caused by CVF complement depletion
(Table 2). The complement depletion could be blocking
crescent formation by inhibiting a specific anti-MPO-me-
diated mechanism or by reducing the synergistic stimu-
lation of concurrent immune complex disease or both.
Mice Deficient in C5 Are Resistant to Anti-MPO
ANCA-Induced NCGN
To confirm the observation that complement plays a role in
anti-MPO-induced NCGN, C5-deficient mice (n  7) were
injected with anti-MPO IgG and compared with WT mice
(n  8) injected with the same dose of anti-MPO IgG. By
day 6 after receiving anti-MPO antibodies, all WT mice
developed albuminuria, leukocyturia, and hematuria,
whereas none of the C5/ mice that received anti-MPO
developed significant albuminuria, leukocyturia, and hema-
turia (Figure 7, A and B). All eight WT mice sacrificed 6 days
after injecting anti-MPO IgG developed glomerulonephritis
with crescents (mean 13% of glomeruli with crescents) and
necrosis (mean 5% of glomeruli with necrosis) (Figures 7C
and 8A). In contrast, none of the C5/ mice injected with
the same dose of anti-MPO IgG had glomerular necrosis or
crescents (Figures 7C and 8B). At day 6, immunofluores-
cence microscopy of glomeruli showed a paucity of glomer-
ular IgG and C3 in WT mice and no IgG or C3 staining in
C5/ mice; and ELISA showed similarly high levels of
circulating anti-MPO IgG in both WT and C5-deficient mice
(data not shown).
The Alternative Pathway but Not the Classic or
Lectin-Binding Pathway Is Required for
Induction of NCGN by Anti-MPO IgG
To gain insight into the relative roles of the three different
pathways of complement activation in the mediation of
anti-MPO induced NCGN, we evaluated the induction of
NCGN by anti-MPO IgG in mice deficient in C4 or factor
B (fB). C4 is required for activation through both the
classic pathway and the lectin-binding pathway; whereas
fB is required for activation through the alternative path-
way. WT (n  8), C4/ (n  6), and fB/ (n  8) were
injected intravenously with the same nephritogenic dose
of anti-MPO IgG. Six days after injection, all WT mice and
C4/ mice developed albuminuria, leukocyturia, and
hematuria; however, none of the fB/ mice developed
urine abnormalities outside the reference range (Figure 9,
A and B). Histological examination of glomeruli on day 6
Figure 6. Circulating C3 and anti-MPO IgG levels in Rag2/ mice during
induction of NCGN. Rag2/ mice that received pretreatment of CVF or PBS
(n  8 for each group) were injected with 5  107 anti-MPO splenocytes.
Circulating C3 and anti-MPO IgG were monitored by ELISA at different time
points up to 13 days after receiving splenocytes. A: Circulating C3 levels in
CVF-treated Rag2/ mice (open squares) and control Rag2/ mice
(filled squares). B: Circulating anti-MPO IgG levels in CVF-treated Rag2/
mice (open squares) and control Rag2/ mice (filled squares). Bars
represent the SD.
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after injection of anti-MPO IgG revealed that all WT and
C4/ mice had glomerular necrosis and crescents of
similar severity (Figures 9C and 10). Crescents involved
an average of 16.7% of glomeruli in WT mice and 17.6%
in C4/ mice. Necrosis involved an average of 7.3% of
glomeruli in WT mice and 8.7% in C4/ mice. In striking
contrast, none of the fB/ mice that received the same
dose of anti-MPO IgG developed renal lesions (Figures
9C and 10). Anti-MPO IgG serum levels in WT, C4/,
and fB/ mice determined by ELISA were the same in all
three groups of mice on day 6 (Figure 9D).
Stimulation of Human Neutrophils by ANCA IgG
Causes Complement Activation
We hypothesized that activation of neutrophils by ANCA
IgG results in the release of factors that cause comple-
ment activation, which in turn amplifies the recruitment
and activation of more neutrophils. To test this hypothe-
sis, we incubated TNF--primed normal human neutro-
phils with IgG isolated from patients with MPO-ANCA
(anti-MPO) (n  6) or PR3-ANCA (anti-PR3) (n  8), or
IgG from ANCA-negative healthy controls (n  8). After
15 minutes, the suspensions were centrifuged and the
supernatants from the reaction mixtures were added to
normal human serum from the donor of the neutrophils.
Complement activation was determined by ELISA mea-
surement of C3a generation. Figure 11 demonstrates that
anti-MPO IgG and anti-PR3 IgG but not control IgG in-
duced neutrophils to release factors that caused comple-
ment activation with generation of C3a. An analysis of
variance comparing the ranked values of the three
groups gave a P value of 0.0016. Using a Duncan’s
multiple range test both the MPO-ANCA and PR3-ANCA
groups had statistically greater complement activation
Figure 7. Lack of C5 blocked induction of NCGN by anti-MPO IgG. WT (n 
8) and C5/ (n  7) mice were injected intravenously with anti-MPO IgG.
Six days after injection, urine and kidney samples were taken and examined.
A and B: Urine albumin was determined by ELISA (A), and leukocyturia and
hematuria were analyzed by dipsticks and expressed as the mean on a scale
of 0 (none) to 4 (severe) (B). C: The extent of glomerular crescents and
necrosis were expressed as the mean percentage of glomeruli with necrosis
and crescents. Bars represent the SD. *P  0.004.
Figure 8. Six days after injection of anti-Mpo IgG, histological examination
revealed glomerular necrosis and crescents (arrows) in all WT mice (A) but
no glomerular lesion in C5/ mice that received the same dose of anti-MPO
IgG (B). H&E stain.
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than the control group; however, the MPO-ANCA group
was not different from the PR3-ANCA group. A nonpara-
metric version of the analysis of variance (Kruskal-Wallis
test) gave a P value of 0.0058, which further confirmed
the differences between the groups. Anti-MPO IgG, anti-
PR3 IgG, and control IgG in the absence of neutrophils
did not cause C3a generation (Figure 11). TNF--primed
neutrophils incubated under the same conditions in the
absence of any IgG did not release factors that activated
complement. Thus, ANCA-induced activation of human
neutrophils results in the release of factors that cause
complement activation.
Discussion
Microscopic polyangiitis, Wegener’s granulomatosis,
Churg-Strauss syndrome, and renal limited NCGN are
manifestations of ANCA-associated small vessel vascu-
litis and glomerulonephritis.30 The acute pathological le-
Figure 9. Mice deficient in fB but not C4 were resistant to anti-MPO IgG-induced NCGN. WT (n  8), fB/ (n  8), and C4/ (n  6) mice were injected
intravenously with anti-MPO IgG and examined 6 days later. A and B: WT and C4/ mice that received anti-MPO IgG showed albuminuria, leukocyturia, and
hematuria, but fB/ mice that received anti-MPO antibody had no urine abnormalities. Crescents and necrosis were observed in glomeruli of all WT and C4/
mice that received anti-MPO IgG. No glomerular injury was seen in fB/ mice injected with same amount of anti-MPO IgG. C: The extent of glomerular damage
was expressed as the mean percentage of glomeruli with crescents and necrosis. D: Circulating anti-MPO antibody titers determined by ELISA were similar in WT,
fB/, and C4/ mice. Bars represent the SD. *P  0.005.
Figure 10. A and B: Crescents and necrosis were observed in glomeruli of all WT mice (A) and all C4/ mice (B) that received anti-MPO IgG (arrows). C: No
glomerular injury was seen in fB/ mice injected with same amount of anti-MPO IgG. H&E stain.
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sions in each of these expressions of ANCA disease are
characterized by extensive neutrophil infiltration, leuko-
cytoclasia, and necrosis.18,19,30 As demonstrated in the
current and previous studies,4,6,7 vascular and glomeru-
lar inflammation and necrosis that is virtually identical to
human ANCA disease is produced by administration of
anti-MPO IgG to mice. Neutrophils are required for the
induction of this injury.7 In this study, we have demon-
strated that induction of glomerulonephritis with anti-MPO
IgG or anti-MPO splenocytes requires the alternative
complement pathway but not the classic pathway or the
lectin pathway.
The complement system complements the mediation
of inflammation through three pathways that are initiated
by diverse stimuli and augment inflammation initiated
both by the innate and adaptive immune responses.21
The classic pathway amplifies injury initiated by antibody
binding to antigen, and thus interfaces with adaptive
immune responses. The classic pathway also can be
activated by innate immune responses through interac-
tion with C-reactive protein.22 The lectin pathway is acti-
vated by pattern recognition of carbohydrate ligands,
such as mannose, that are expressed by infectious
pathogens. The classic and lectin pathways are unidirec-
tional and thus are not self-sustaining if the stimulus is
eliminated. In contrast, the alternative pathway is self-
sustaining and thus acts as an amplification loop for
inflammation that continues until it is down-regulated by
specific control proteins, such as factor H and factor I.23
The alternative pathway begins with amplification of con-
stitutive low-level C3 autoactivation, called “tickover,”
which occurs normally and is held in check by control
proteins unless an added impetus fully activates the am-
plification loop.
Activation of the classic, lectin, and alternative com-
plement pathways all result in the conversion of C3 to
C3b and C3a.21 The classic and lectin pathways gener-
ate the same C3 convertase (C4bC2b), whereas the al-
ternative pathway generates a different C3 convertase
(C3bBbP). Likewise, the classic and lectin pathways gen-
erate the same C5 convertase (C3bC4bC2b), whereas
the alternative pathway generates a different C5 conver-
tase (C3b2BbP). Thus, all three pathways converge at
the activation of C5 to form the potent chemoattractant
C5a and the membrane attack complex C5b-9. Thus C3
and C5 are required for activation of complement by
each of the three pathways.
In both the anti-MPO IgG and anti-MPO splenocyte
transfer mouse models of ANCA disease, pretreatment
with Cobra venom factor, which causes extensive deple-
tion of C3,31 completely blocked the induction of NCGN
(Table 1). Likewise C5/ mice were completely pro-
tected from the induction of NCGN by anti-MPO IgG
(Figure 7). The absence of complement activation not
only prevented the induction of glomerular necrosis and
crescents, but also abrogated the marked influx of neu-
trophils and monocytes that is typical of this model (Table
1), probably because of blockade of generation of C5a,
which is a potent chemoattractant and activator of neu-
trophils. Rather than total absence of complement-acti-
vating capacity, there may be a critical level of comple-
ment depletion below which lesions do not develop.
Future studies will be needed to determine how much
depression of complement activation is required to com-
pletely block disease induction.
Both the classic and lectin pathways require activation
of C4 to produce C3 convertase (C4bC2b) and C5 con-
vertase (C3bC4bC2b). C4/ mice are unable to gener-
ate these convertases and thus cannot activate C3 or C5.
Nevertheless, there was no protection of C4/ mice from
the induction of NCGN by anti-MPO IgG (Figure 9). This
observation indicates that neither the classic nor lectin
pathways of complement activation are required for the
induction of this model of ANCA NCGN. This observation
also substantiates the contention that ANCA disease is
not a form of typical immune complex mediated inflam-
mation, which involves activation of complement via the
classic or alternative pathways.21,32 In marked contrast,
the absence of the alternative pathway component factor
B completely protected fB/ mice from induction of
NCGN by anti-MPO IgG (Figure 9). This requirement for
factor B in the absence of a requirement for C4 indicates
that the mediation of the inflammation involves the alter-
native pathway but not the classic or lectin pathways.
Based on the evidence reviewed in the introduction
that ANCA IgG activates cytokine-primed neutrophils8–17
and reports in the literature that activated neutrophils
release factors that can activate the alternative comple-
ment pathway,24–27 we hypothesized that activation of
neutrophils by ANCA IgG causes the release of factors
that activate complement. This hypothesis was substan-
tiated by demonstrating that activation of human neutro-
phils by human MPO-ANCA or PR3-ANCA IgG releases
factors that activate complement with the generation of
C3a (Figure 11). These studies do not identify what factor
or factors are responsible for the complement activation,
but a number of candidates are suggested by the litera-
Figure 11. Incubation of TNF--primed normal human neutrophils with
human anti-MPO IgG or anti-PR3 IgG caused release of factors that caused
complement activation in normal serum as detected by generation of C3a.
Normal TNF--primed neutrophils were first incubated with IgG and then the
supernatant was reacted with normal serum and the activation of comple-
ment measured by C3a ELISA. C3a generation is expressed as a percentage of
the mean of the results for control IgG. Anti-MPO IgG and anti-PR3 IgG
caused C3a generation at 173.3 and 146.4%, respectively, compared with
control IgG. The normal control replicate assays averaged 98.2%. The C3a
generation by both anti-MPO and anti-PR3 ANCA was statistically significant
compared with control (P  0.0016). No C3a generation was caused by
anti-MPO IgG, anti-PR3 IgG, or normal control IgG alone; or by TNF--
primed neutrophils in the absence of IgG.
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ture, including reactive oxygen radicals,24 MPO,25 pro-
teases,26 and properdin.27 Properdin is synthesized by
neutrophils and stored in secondary granules that are
released on activation.33 C5a stimulates properdin re-
lease from neutrophils.32 Thus, ANCA activation of neu-
trophils could set in motion a cycle of properdin release
with C5a generation that in turn causes more neutrophil
recruitment, activation, and properdin release to perpet-
uate the cycle.
Once the alternative pathway is activated, it is self-
sustaining and thus acts as an amplification loop for
inflammation that continues until it is down-regulated by
specific control proteins, such as factor H and factor I.23
In a microenvironment containing immune complexes,
eg, ANCA antibodies bound to ANCA antigens, C3b can
associate with the Fc region of immunoglobulins and be
protected from regulatory proteins,34 which could further
enhance the amplification of inflammatory injury at sites
of ANCA disease.
In conclusion, supported by the observations reported
in this article, we propose that stimulation of neutrophils
by ANCA IgG caused the release of factors that activate
complement via the alternative pathway, which initiates
an inflammatory amplification loop that mediates the se-
vere necrotizing inflammation of ANCA disease (Figure
12).
Acknowledgments
We thank Dr. Susan Hogan for statistical analysis, Dr.
Jiajin Yang for ANCA IgG, and Dr. Bei Zhang and Ms. Jue
Yao for expert technical assistance.
References
1. Jennette JC, Xiao H, Falk RJ: The pathogenesis of vascular inflam-
mation by antineutrophil cytoplasmic antibodies. J Am Soc Nephrol
2006, 17:1235–1242
2. Bansal PJ, Tobin MC: Neonatal microscopic polyangiitis secondary to
transfer of maternal myeloperoxidase-antineutrophil cytoplasmic an-
tibody resulting in neonatal pulmonary hemorrhage and renal involve-
ment. Ann Allergy Asthma Immunology 2004, 93:398–401
3. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ: Pul-
monary-renal syndrome in a newborn with placental transmission of
ANCAs. Am J Kidney Dis 2005, 45:758–761
4. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ,
Jennette JC: Antineutrophil cytoplasmic autoantibodies specific for
myeloperoxidase cause glomerulonephritis and vasculitis in mice.
J Clin Invest 2002, 110:955–963
Figure 12. Diagram depicting a putative pathogenic mechanism for ANCA glomerulonephritis and vasculitis. Beginning in the top left, neutrophils are primed by
cytokines to express more ANCA antigens (MPO and PR3) at the surface where they can interact with ANCA antibodies. This results in neutrophil activation both
by Fc receptor engagement and Fab2 binding. ANCA-activated neutrophils release factors (eg, properdin, proteases, oxygen radicals, and MPO) that activate the
alternative complement pathway with the generation of the powerful neutrophil chemoattractant C5a and the membrane attack complex C5b-9. This complement
activation amplifies neutrophil influx, neutrophil activation, and vessel damage, resulting in the aggressive necrotizing inflammation of ANCA disease.
Role of Complement in ANCA Disease 63
AJP January 2007, Vol. 170, No. 1
5. Little MA, Smyth CL, Yadav R, Ambrose L, Cook HT, Nourshargh S,
Pusey CD: Anti-neutrophil cytoplasm antibodies directed against my-
eloperoxidase augment leukocyte-microvascular interactions in vivo.
Blood 2005, 106:2050–2058
6. Huugen D, Xiao H, van Esch A, Falk RJ, Peutz-Kootstra CJ, Buurman
WA, Tervaert JW, Jennette JC, Heeringa P: Aggravation of anti-
myeloperoxidase antibody-induced glomerulonephritis by bacterial
lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol
2005, 167:47–58
7. Xiao H, Heeringa P, Liu Z, Huugen D, Hu P, Maeda N, Falk RJ,
Jennette JC: The role of neutrophils in the induction of glomerulone-
phritis by anti-myeloperoxidase antibodies. Am J Pathol 2005,
167:39–45
8. Falk RJ, Terrell R, Charles LA, Jennette JC: Anti-neutrophil cytoplas-
mic autoantibodies induce neutrophils to degranulate and produce
oxygen radicals. Proc Natl Acad Sci USA 1990, 87:4115–4119
9. Charles LA, Caldas ML, Falk RJ, Terrell RS, Jennette JC: Antibodies
against granule proteins activate neutrophils in vitro. J Leuk Biol 1991,
50:539–546
10. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kim-
berly RP: Anti-neutrophil cytoplasmic antibodies engage and activate
human neutrophils via Fc gamma RIIa. J Immunol 1994,
153:1271–1280
11. Mulder AH, Heeringa P, Brouwer E, Limburg PC, Kallenberg CG:
Activation of granulocytes by anti-neutrophil cytoplasmic antibodies
(ANCA): a Fc gamma RII-dependent process. Clin Exp Immunol
1994, 98:270–278
12. Kettritz R, Jennette JC, Falk RJ: Crosslinking of ANCA-antigens stim-
ulates superoxide release by human neutrophils. J Am Soc Nephrol
1997, 8:386–394
13. Williams JM, Ben-Smith A, Hewins P, Dove SK, Hughes P, McEwan R,
Wakelam MJ, Savage CO: Activation of the G(i) heterotrimeric G
protein by ANCA IgG F(ab)2 fragments is necessary but not suffi-
cient to stimulate the recruitment of those downstream mediators
used by intact ANCA IgG. J Am Soc Nephrol 2003, 14:661–669
14. Radford DJ, Savage CO, Nash GB: Treatment of rolling neutrophils
with antineutrophil cytoplasmic antibodies causes conversion to firm
integrin-mediated adhesion. Arthritis Rheum 2000, 43:1337–1345
15. Radford DJ, Luu NT, Hewins P, Nash GB, Savage CO: Antineutrophil
cytoplasmic antibodies stabilize adhesion and promote migration of
flowing neutrophils on endothelial cells. Arthritis Rheum 2001,
44:2851–2861
16. Ewert BH, Jennette JC, Falk RJ: Anti-myeloperoxidase antibodies
stimulate neutrophils to damage human endothelial cells. Kidney Int
1992, 41:375–383
17. Savage CO, Pottinger BE, Gaskin G, Pusey CD, Pearson JD: Auto-
antibodies developing to myeloperoxidase and proteinase 3 in sys-
temic vasculitis stimulate neutrophil cytotoxicity toward cultured en-
dothelial cells. Am J Pathol 1992, 141:335–342
18. Jennette JC, Wilkman AS, Falk RJ: Anti-neutrophil cytoplasmic au-
toantibody-associated glomerulonephritis and vasculitis. Am J Pathol
1989, 135:921–930
19. Jennette JC: Implications for pathogenesis of patterns of injury in
small and medium-sized vessel vasculitis. Cleveland Clinic J Med
2002, 69:SII33–SII38
20. Riedemann NC, Ward PA: Complement in ischemia reperfusion in-
jury. Am J Pathol 2003, 162:363–367
21. Seelen MA, Roos A, Daha MR: Role of complement in innate and
autoimmunity. J Nephrol 2005, 18:642–653
22. Agrawal A: CRP after 2004. Mol Immunol 2005, 42:927–930
23. Thurman JM, Holers VM: The central role of the alternative comple-
ment pathway in human disease. J Immunol 2006, 176:1305–1310
24. Shingu M, Nonaka S, Nishimukai H, Nobunaga M, Kitamura H, Tomo-
Oka K: Activation of complement in normal serum by hydrogen per-
oxide and hydrogen peroxide-related oxygen radicals produced by
activated neutrophils. Clin Exp Immunol 1992, 90:72–78
25. Vogt W: Complement activation by myeloperoxidase products re-
leased from stimulated human polymorphonuclear leukocytes. Immu-
nobiology 1996, 195:334–346
26. Venge P, Olsson I: Cationic proteins of human granulocytes. VI.
Effects on the complement system and mediation of chemotactic
activity. J Immunol 1975, 115:1505–1508
27. Wirthmueller U, Dewald B, Thelen M, Schafer MK, Stover C, Whaley
K, North J, Eggleton P, Reid KB, Schwaeble WJ: Properdin, a positive
regulator of complement activation, is released from secondary gran-
ules of stimulated peripheral blood neutrophils. J Immunol 1997,
158:4444–4451
28. Aratani Y, Koyama H, Nyui S, Suzuki K, Kura F, Maeda N: Severe
impairment in early host defense against Candida albicans in mice
deficient in myeloperoxidase. Infect Immun 1999, 67:1828–1836
29. Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoen-
berger J, Wang X, Fujita S, Hidvegi T, Chaplin DD, Colten HR:
Abrogation of the alternative complement pathway by targeted dele-
tion of murine factor B. Proc Natl Acad Sci USA 1997, 94:8720–8725
30. Jennette JC, Falk RJ: Small vessel vasculitis. N Engl J Med 1997,
337:1512–1523
31. Cochrane CG, Muller-Eberhard HJ, Aikin BS: Depletion of plasma
complement in vivo by a protein of cobra venom: its effect on various
immunologic reactions. J Immunol 1970, 105:55–69
32. Hisano S, Matsushita M, Fujita T, Iwasaki H: Activation of the lectin
complement pathway in Henoch-Schonlein purpura nephritis. Am J
Kidney Dis 2005, 45:295–302
33. Schwaeble WJ, Reid KB: Does properdin crosslink the cellular and
the humoral immune response? Immunol Today 1999, 20:17–21
34. Lutz HU, Jelezarova E: Complement amplification revisited. Mol Im-
munol 2006, 43:2–12
64 Xiao et al
AJP January 2007, Vol. 170, No. 1
